Tenofovir Alafenamide (TAF) as Long-Term Therapy for Chronic Hepatitis B: Is It the Best Choice?

Authors

  • Irsan Hasan Division of Hepatology, Department of Internal Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta

DOI:

https://doi.org/10.24871/2332022173

Abstract

-

Downloads

Published

2022-12-26

How to Cite

Hasan, I. (2022). Tenofovir Alafenamide (TAF) as Long-Term Therapy for Chronic Hepatitis B: Is It the Best Choice?. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 23(3), 173. https://doi.org/10.24871/2332022173

Issue

Vol. 23 No. 3 (2022): VOLUME 23, NUMBER 3, December 2022

Section

Editorial

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).